Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients
Fabio M. Pulcinelli, PhD, MD*,*,
Pasquale Pignatelli, PhD, MD*,
Andrea Celestini, MD*,
Silvia Riondino, PhD, MD*,
Pier Paolo Gazzaniga, MD* and
Francesco Violi, MD*
* Department of Experimental Medicine and Pathology, University "La Sapienza," Rome, Italy
View larger version (23K):
[in a new window]
|
Figure 1 Box plot of the lag phase of platelet aggregation induced by collagen (2 µg/ml) before and after 2, 6, 12, and 24 months of aspirin treatment. NS = not significant.
|
|
View larger version (24K):
[in a new window]
|
Figure 2 Box plot of the maximal percentage (Mx%) of platelet aggregation induced by collagen (2 µg/ml) before and after 2, 6, 12, and 24 months of aspirin treatment. NS = not significant.
|
|
View larger version (21K):
[in a new window]
|
Figure 3 Box plot of the maximal percentage (Mx%) of platelet aggregation induced by adenosine diphosphate (ADP) (2 µmol/l) before and after 2, 6, 12, and 24 months of aspirin treatment. NS = not significant.
|
|
View larger version (14K):
[in a new window]
|
Figure 4 Platelet aggregation (mean ± SEM) analyzed as lag phase and maximal percentage (Mx%) of aggregation in response to collagen (2 µg/ml) and as Mx% in response to adenosine diphosphate (ADP) (2 µmol/l) at baseline and throughout follow-up in patients given 100 mg/day or 300 to 330 mg/day aspirin.
|
|
View larger version (36K):
[in a new window]
|
Figure 5 Platelet aggregation (mean ± SEM) analyzed as lag phase and maximum percentage of aggregation (Mx%) in response to collagen (2 µg/ml) and as Mx% in response to adenosine diphosphate (ADP) (2 µmol/l) at baseline and throughout follow-up in hypertensive and hypercholesterolemic patients.
|
|
|
